ReachMD CME

CME credits: 0.25 Valid until: 24-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/ready-set-act-opportunities-to-address-persistent-unmet-needs-in-patients-with-hfref-a-case-based-discussion/57260/ Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing persistent residual risk, and using biomarkers such as NT-proBNP to guide treatment decisions. Faculty also review the mechanism of action of the soluble guanylate cyclase stimulator vericiguat and evidence from the VICTORIA and VICTOR trials evaluating its use across a spectrum of ambulatory HFrEF populations, as well as findings from the VELOCITY study supporting a 5-mg starting dose and simplified titration to the target dose. Practical guidance is provided on integrating vericiguat with established HFrEF therapies, including patient selection, dosing, and tolerability, with the goal of reducing the risk of cardiovascular death and worsening heart failure in appropriate patients.=

CME credits: 1.00 Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/frontline-champions-nurses-as-drivers-of-symptom-based-ckd-ap-care/54094/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

CME credits: 1.00 Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/what-you-dont-see-a-patients-view-of-living-with-ckd-ap/60999/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

CME credits: 1.00 Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/winning-the-ckd-ap-battle-a-united-physician-nurse-front/61000/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-code-risk-stratification-guidelines-to-identify-high-risk-patients/57192/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-timing-therapies-that-change-outcomes/57193/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/adt-intensification-in-biochemically-recurrent-prostate-cancer-when-to-act/57194/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-in-practicebringing-targeted-therapy-to-mhspc/57201/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-rett-syndrome-a-lifespan-approach-to-clinical-recognition/57129/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-recognizing-rett-syndrome-early-signs-and-diagnosis/57130/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57131/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-rett-syndrome-management-practical-approaches-to-multidisciplinary-care/57132/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57133/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-adult-rett-syndrome-care-supporting-long-term-needs/57134/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/transitioning-to-adult-care-in-rett-syndrome-navigating-challenges/57135/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-transition-supporting-patients-and-families-into-adulthood/57136/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-first-line-treatment-of-metastatic-tnbc/60632/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/comparing-first-line-trop2-directed-adcs-in-metastatic-tnbc-latest-clinical-evidence/60633/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-first-line-treatment-in-metastatic-tnbc-ineligible-for-immunotherapy/60634/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-trop2-directed-adcs-in-metastatic-tnbc/60635/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-first-line-treatment-of-metastatic-tnbc/60636/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-on-trop2-directed-adcs-into-global-practice-in-metastatic-tnbc/60637/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.25 Valid until: 15-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-to-match-choosing-the-right-vmat2-strategy-for-the-patient/54717/ This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMAT2 inhibitors, including factors such as speed of response, durability, tolerability, and regimen simplicity. It also addresses treatment selection in the setting of polypharmacy, with attention to CYP2D6 and CYP3A4 interactions, dose limitations, titration, and practical issues such as insurance access. In addition, the discussion highlights follow-up considerations after treatment initiation, including assessment of response, tolerability, and patient satisfaction, to support ongoing management decisions in clinical practice.=

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.=

CME credits: 0.25 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-fsgs-a-case-based-approach-in-the-new-era-of-targeted-therapy/35906/ Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatment landscape evolves, clinicians must understand how emerging therapies may influence disease management and patient outcomes.Join Drs. Jörg Latus and Sayna Norouzi as they review the latest evidence in FSGS, including clinical data supporting the use of sparsentan in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. The faculty will explore practical considerations for treatment selection, monitoring, and long-term disease management.=

CME credits: 1.00 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-sleep-the-broader-connection-between-the-orexin-system-and-psychiatric-disorders/48749/ Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors, including orexin-driven arousal mechanisms, REM sleep abnormalities, limited use of validated screening tools, and incomplete differential diagnoses for hypersomnia, can further impair quality of life and outcomes. This broadcast replay will help improve clinicians' understanding of the biological link between sleep regulation and mood dysregulation, better known as the orexin system, to support a shift from fragmented, symptom-based management to integrated, mechanism-driven care.=

CME credits: 0.25 Valid until: 09-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-incorporating-novel-treatment-options-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/54751/ Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor dysfunction in schizophrenia, leading to the development of therapies with mechanisms distinct from dopamine blockade. This Chairperson's Perspective reviews clinical data for xanomeline–trospium and discusses practical considerations for integrating muscarinic therapies into practice, including patient selection, treatment sequencing, dosing, and management of gastrointestinal and autonomic adverse effects. Are you prepared to incorporate muscarinic agents into the treatment of schizophrenia? Tune in for an overview of the latest data.=

CME credits: 1.00 Valid until: 07-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-through-the-continuum-applying-biomarker-guided-therapies-in-ovarian-cancer/56953/ This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants will apply biomarker insights to guide treatment strategies in both frontline maintenance and platinum-resistant settings. Faculty emphasize patient selection, sequencing strategies, and interpretation of clinical data within real-world practice constraints. The program also highlights proactive approaches to identifying and managing treatment-related adverse events to support adherence and quality of life. This activity equips clinicians with practical tools to integrate biomarker findings, clinical evidence, and patient-centered considerations into individualized ovarian cancer care. =

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/why-staging-ted-correctly-matters-even-when-cas-is-low/60939/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/applying-cas-eugogo-visa-a-micro-case/60940/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/why-qol-measures-change-ted-management/60941/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-real-world-barriers-to-ted-treatment/60942/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/designing-efficient-clinic-workflows-for-ted-therapy-access/60943/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/understanding-igf-1r-inhibition-mechanism-clinical-implications/60944/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/comparing-trial-designs-outcomes-across-igf-1r-therapies/60945/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-igf-1r-il-6r-inhibition-and-future-sequencing/60946/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients' true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

CME credits: 1.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/ A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems. =

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Cracking-the-Code-in-Localized-nmCSPC-Risk-Treatment-and-Timing/56686/ In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment intensification, including androgen deprivation therapy–based combination approaches and the earlier use of androgen receptor pathway inhibitors in patients with high-risk disease. They also explore how advances in imaging, multidisciplinary care, and emerging clinical evidence are shaping treatment selection and timing. In addition, the discussion addresses practical considerations for managing adverse events associated with intensified therapy and incorporating these strategies into clinical practice. =

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-mCSPC-Molecular-Profiling-and-Biomarker-Directed-Therapies/56688/ This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined. =

CME credits: 0.25 Valid until: 24-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/screening-workup-hypercortisolism-resistant-hypertension/50076/ With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare providers screen, and what straightforward testing methods can be used to detect and confirm hypercortisolism with confidence? Once identified, how might earlier intervention alter the course of disease progression?=

CME credits: 0.50 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/reimagining-alzheimers-care-the-advent-of-subcutaneous-administration-of-anti-amyloid-therapy/39878/ In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer's disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.=

CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.=